The Company will host its earnings conference call via webcast.
July 23, 2024, Victoria, British Columbia–(BUSINESS WIRE)–ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA) today announced that it is rescheduling its presentation of its full year 2024 financial results and business highlights. The presentation date, originally scheduled for July 25, 2024, will now be Monday, July 29, 2024, with the Company holding an earnings conference call on that day at 10:30 a.m. Eastern Time.
We are allowing additional time for our auditors to complete the required valuation calculations of goodwill and intangible assets. This extension will ensure that our financial data accurately reflects the value of our company and complies with all regulatory requirements. This delay will allow for a comprehensive and accurate valuation, which is critical to our financial health.
A live audio webcast of the earnings call will be accessible via a link provided on IPA’s Investor Relations website at ir.ipatherapeutics.com. A replay will be archived and available for playback following the call.
Conference call:
Event Title: ImmunoPrecise Reports Full Year 2024 Financial Performance and Recent Business Highlights
Event date: July 29, 2024
Time: 10:30 AM (GMT-04:00) Eastern Time (US & Canada)
***Participant Dial-in Details***
Participants will call one of the assigned dial-in numbers (below) and provide an operator with the conference ID 9236374 or the conference name.
North America Toll Free: (888) 550-5658
North American Toll: (646) 960-0289
International: +1(646) 960-0289
***Webcast Details***
Attendee URL: https://events.q4inc.com/attendee/388047633
A live audio webcast of the earnings call will be accessible via a link provided on IPA’s Investor Relations website at ir.ipatherapeutics.com. A replay will be archived and available for playback following the call.
About ImmunoPrecise Antibodies Ltd.
IPA Family is a biotherapeutic research and technology group leveraging systems biology, multi-omics modeling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. Services include highly specialized full-continuum therapeutic biologics discovery, development and licensing, supporting business partners seeking to discover and develop novel biologics against the most challenging targets. ImmunoPrecise Antibodies Ltd. has multiple subsidiaries in North America and Europe, including Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) BV (collectively, the “IPA Family”). For more information, please visit www.ipatherapeutics.com.
Forward-Looking Statements:
This news release contains forward-looking statements within the meaning of applicable U.S. and Canadian securities laws. Forward-looking statements are often identified by the use of words such as “potential,” “plans,” “expects,” “does not expect,” “is expected,” “estimates,” “intends,” “anticipates,” “does not expect,” “believes” or variations of these words and phrases and state that certain actions, events or results “may,” “could,” “would,” “might” or “will” occur. With respect to the forward-looking information contained herein, IPA has based these statements and information on certain assumptions that management believed to be reasonable at the time.
Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements described in this press release to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Actual results may differ materially from those currently expected due to a number of factors and risks detailed in the Company’s Annual Information Form dated July 10, 2023 (available under the Company’s profile at www.sedar.com) and the Company’s Form 40-F dated July 10, 2023 (available under the Company’s profile at www.sec.gov). Should one or more of these risks or uncertainties materialize, or should the assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements may differ materially from those expressed or implied by the forward-looking statements contained in this news release. Readers should therefore not place undue reliance on the forward-looking information contained in this news release. The forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. The Company undertakes no obligation to update or revise any written or oral forward-looking statements that may be made from time to time by the Company or any person acting on its behalf, except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240723337852/ja/
contact address
Investor: investors@ipatherapeutics.com
